Elena Prokupets Sells 10,321 Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC) Stock

C4 Therapeutics, Inc. (NASDAQ:CCCC) Director Elena Prokupets sold 10,321 shares of the stock in a transaction dated Tuesday, September 21st. The shares were sold at an average price of $50.14, for a total value of $517,494.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Elena Prokupets also recently made the following trade(s):

  • On Friday, September 17th, Elena Prokupets sold 10,840 shares of C4 Therapeutics stock. The shares were sold at an average price of $50.05, for a total value of $542,542.00.
  • On Wednesday, September 15th, Elena Prokupets sold 54,193 shares of C4 Therapeutics stock. The shares were sold at an average price of $48.82, for a total value of $2,645,702.26.
  • On Monday, September 13th, Elena Prokupets sold 6,660 shares of C4 Therapeutics stock. The shares were sold at an average price of $50.07, for a total value of $333,466.20.
  • On Friday, September 10th, Elena Prokupets sold 2,550 shares of C4 Therapeutics stock. The shares were sold at an average price of $50.00, for a total value of $127,500.00.
  • On Monday, August 2nd, Elena Prokupets sold 4,257 shares of C4 Therapeutics stock. The shares were sold at an average price of $45.01, for a total value of $191,607.57.
  • On Thursday, July 29th, Elena Prokupets sold 11,336 shares of C4 Therapeutics stock. The shares were sold at an average price of $45.00, for a total value of $510,120.00.

C4 Therapeutics stock traded up $1.39 during mid-day trading on Tuesday, reaching $50.06. 227,077 shares of the company’s stock were exchanged, compared to its average volume of 363,740. The business’s fifty day simple moving average is $42.63 and its 200 day simple moving average is $38.96. The firm has a market capitalization of $2.43 billion and a PE ratio of -8.59. C4 Therapeutics, Inc. has a one year low of $22.40 and a one year high of $50.62. The company has a quick ratio of 10.81, a current ratio of 10.81 and a debt-to-equity ratio of 0.02.

C4 Therapeutics (NASDAQ:CCCC) last issued its quarterly earnings results on Tuesday, August 10th. The company reported ($0.51) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.59) by $0.08. The business had revenue of $9.78 million for the quarter, compared to analyst estimates of $7.45 million. C4 Therapeutics had a negative return on equity of 43.32% and a negative net margin of 257.05%. On average, sell-side analysts forecast that C4 Therapeutics, Inc. will post -2.32 earnings per share for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Nisa Investment Advisors LLC purchased a new position in shares of C4 Therapeutics in the second quarter valued at $26,000. O Shaughnessy Asset Management LLC purchased a new position in shares of C4 Therapeutics in the first quarter valued at $38,000. E Fund Management Co. Ltd. purchased a new position in shares of C4 Therapeutics in the first quarter valued at $72,000. Ameritas Investment Partners Inc. grew its position in C4 Therapeutics by 202.0% during the second quarter. Ameritas Investment Partners Inc. now owns 2,700 shares of the company’s stock worth $102,000 after buying an additional 1,806 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in C4 Therapeutics during the first quarter worth about $147,000. Institutional investors own 65.94% of the company’s stock.

CCCC has been the topic of a number of recent research reports. BMO Capital Markets raised their target price on C4 Therapeutics from $53.00 to $55.00 and gave the company an “outperform” rating in a report on Tuesday, June 22nd. Brookline Capital Management restated a “buy” rating on shares of C4 Therapeutics in a report on Friday, June 25th. HC Wainwright started coverage on C4 Therapeutics in a report on Friday, June 4th. They issued a “buy” rating and a $63.00 target price on the stock. Finally, Brookline Capital Acquisition started coverage on C4 Therapeutics in a report on Thursday, June 24th. They set a “buy” rating and a $54.00 price target on the stock. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, C4 Therapeutics has a consensus rating of “Buy” and an average target price of $51.50.

About C4 Therapeutics

C4 Therapeutics, Inc, a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma.

See Also: Initial Coin Offering (ICO)

Insider Buying and Selling by Quarter for C4 Therapeutics (NASDAQ:CCCC)

Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.